Endogenously produced nonclassical vitamin D hydroxy-metabolites act as "biased" agonists on VDR and inverse agonists on RORα and RORγ.
The classical pathway of vitamin D activation follows the sequence D3→25(OH)D3→1,25(OH)2D3 with the final product acting on the receptor for vitamin D (VDR). An alternative pathway can be started by the action of CYP11A1 on the side chain of D3, primarily producing 20(OH)D3, 22(OH)D3, 20,23(OH)2D3, 20,22(OH)2D3 and 17,20,23(OH)3D3. Some of these metabolites are hydroxylated by CYP27B1 at C1α, by CYP24A1 at C24 and C25, and by CYP27A1 at C25 and C26. The products of these pathways are biologically active. In the epidermis and/or serum or adrenals we detected 20(OH)D3, 22(OH)D3, 20,22(OH)2D3, 20,23(OH)2D3, 17,20,23(OH)3D3, 1,20(OH)2D3, 1,20,23(OH)3D3, 1,20,22(OH)3D3, 20,24(OH)2D3, 1,20,24(OH)3D3, 20,25(OH)2D3, 1,20,25(OH)3D3, 20,26(OH)2D3 and 1,20,26(OH)3D3. 20(OH)D3 and 20,23(OH)2D3 are non-calcemic, while the addition of an OH at C1α confers some calcemic activity. Molecular modeling and functional assays show that the major products of the pathway can act as "biased" agonists for the VDR with high docking scores to the ligand binding domain (LBD), but lower than that of 1,25(OH)2D3. Importantly, cell based functional receptor studies and molecular modeling have identified the novel secosteroids as inverse agonists of both RORα and RORγ receptors. Specifically, they have high docking scores using crystal structures of RORα and RORγ LBDs. Furthermore, 20(OH)D3 and 20,23(OH)2D3 have been tested in a cell model that expresses a Tet-on RORα or RORγ vector and a RORE-LUC reporter (ROR-responsive element), and in a mammalian 2-hybrid model that test interactions between an LBD-interacting LXXLL-peptide and the LBD of RORα/γ. These assays demonstrated that the novel secosteroids have ROR-antagonist activities that were further confirmed by the inhibition of IL17 promoter activity in cells overexpressing RORα/γ. In conclusion, endogenously produced novel D3 hydroxy-derivatives can act both as "biased" agonists of the VDR and/or inverse agonists of RORα/γ. We suggest that the identification of large number of endogenously produced alternative hydroxy-metabolites of D3 that are biologically active, and of possible alternative receptors, may offer an explanation for the pleiotropic and diverse activities of vitamin D, previously assigned solely to 1,25(OH)2D3 and VDR.
Department of Dermatology, USA; Comprehensive Cancer Center, Cancer Chemoprevention Program, University of Alabama at Birmingham, USA; Pathology and Laboratory Medicine Service, VA Medical Center, Birmingham, AL, 35249, USA. Electronic address: aslominski@uabmc.edu.
Andrzej T
AT
Slominski
Department of Dermatology, USA.
Tae-Kang
TK
Kim
Drug Discovery Unit, College of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom.
Judith V
JV
Hobrath
Department of Dermatology, USA.
Allen S W
ASW
Oak
School of Chemistry and Biochemistry, University of Western Australia, Crawley, WA, Australia.
Edith K Y
EKY
Tang
School of Chemistry and Biochemistry, University of Western Australia, Crawley, WA, Australia.
Elaine W
EW
Tieu
Department of Pharmaceutical Sciences University of Tennessee HSC, Memphis, TN 38163, USA.
Wei
W
Li
School of Chemistry and Biochemistry, University of Western Australia, Crawley, WA, Australia.
Robert C
RC
Tuckey
Cell Biology Section, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, 27709, USA.
Anton M
AM
Jetten
D000818:Animals; D002786:Cholesterol Side-Chain Cleavage Enzyme / Q000378:metabolism; D006801:Humans; D006887:Hydroxycholecalciferols / Q000378:metabolism* / Q000494:pharmacology*; D008958:Models, Molecular; D057094:Nuclear Receptor Subfamily 1, Group F, Member 1 / Q000819:agonists / Q000378:metabolism*; D057132:Nuclear Receptor Subfamily 1, Group F, Member 3 / Q000819:agonists / Q000378:metabolism*; D018167:Receptors, Calcitriol / Q000819:agonists / Q000378:metabolism*; D014815:Vitamins / Q000378:metabolism* / Q000494:pharmacology*
D006887:Hydroxycholecalciferols; D057094:Nuclear Receptor Subfamily 1, Group F, Member 1; D057132:Nuclear Receptor Subfamily 1, Group F, Member 3; D018167:Receptors, Calcitriol; C579457:VDR protein, human; D014815:Vitamins; D002786:Cholesterol Side-Chain Cleavage Enzyme
1,25D3-MARRS; CYP11A1; Hydroxyvitamin D; RORα; RORγ; VDR
Trends Pharmacol Sci. 2014 Sep;35(9):434-41
25042457
Science. 1981 Feb 6;211(4482):590-3
6256855
Front Physiol. 2014 Apr 29;5:167
24808867
Chem Biol. 2014 Mar 20;21(3):319-29
24529992
J Biol Chem. 2004 Apr 16;279(16):15897-907
14757768
N Engl J Med. 2007 Jul 19;357(3):266-81
17634462
Sci Rep. 2015 Oct 08;5:14875
26445902
PLoS One. 2011 Mar 31;6(3):e18124
21483824
Eur J Biochem. 2004 Nov;271(21):4178-88
15511223
Nucl Receptor Res. 2015;2:null
26878025
Physiol Rev. 2016 Jan;96(1):365-408
26681795
Placenta. 2005 Apr;26(4):273-81
15823613
J Invest Dermatol. 2011 May;131(5):1167-9
21228816
J Steroid Biochem Mol Biol. 2017 Jan;165(Pt A):101-108
27060335
Steroids. 2015 Dec;104:153-62
26433048
Drug Metab Dispos. 2013 May;41(5):1112-24
23454830
Steroids. 2015 Nov;103:72-88
25988614
Endocrinology. 2005 Dec;146(12):5581-6
16150907
Steroids. 2001 Mar-May;66(3-5):441-50
11179753
FEBS J. 2008 May;275(10):2585-96
18410379
J Steroid Biochem Mol Biol. 2015 Apr;148:52-63
25617667
J Biol Chem. 2011 Jul 1;286(26):22707-10
21566134
Mol Cell Endocrinol. 2012 Sep 25;361(1-2):143-52
22546549
Endocrine. 2014 May;46(1):29-38
24402695
Handb Exp Pharmacol. 2009;(188):251-73
19031030
Steroids. 2016 Jun;110:49-61
27083311
F1000 Biol Rep. 2009 Nov 26;1:87
20948603
J Steroid Biochem Mol Biol. 2015 Apr;148:47-51
25445917
Drug Metab Dispos. 2009 Apr;37(4):761-7
19116262
J Steroid Biochem Mol Biol. 2014 Oct;144 Pt A:28-39
24176765
Steroids. 2010 Dec;75(12 ):926-35
20542050
Endocr Rev. 2011 Feb;32(1):81-151
21051590
Annu Rev Pharmacol Toxicol. 2001;41:421-42
11264464
Nat Rev Drug Discov. 2010 Dec;9(12):941-55
21119732
FEBS J. 2006 Jul;273(13):2891-901
16817851
J Invest Dermatol. 2008 Sep;128(9):2271-80
18368131
J Invest Dermatol. 1981 Jul;77(1):51-8
6265564
J Cell Biochem. 2003 Feb 1;88(2):296-307
12520530
J Steroid Biochem Mol Biol. 2010 Apr;119(3-5):171-9
20193763
Structure. 2002 Dec;10(12):1697-707
12467577
FASEB J. 2012 Sep;26(9):3901-15
22683847
FEBS J. 2005 Aug;272(16):4080-90
16098191
Chin J Nat Med. 2015 Jul;13(7):481-97
26233839
Best Pract Res Clin Endocrinol Metab. 2011 Aug;25(4):543-59
21872797
Cell Metab. 2015 Feb 3;21(2):286-97
25651181
Anticancer Res. 2014 May;34(5):2153-63
24778017
Steroids. 2001 Mar-May;66(3-5):327-37
11179741
Cell Immunol. 2005 Feb;233(2):115-24
15936743
Nat Rev Drug Discov. 2014 Mar;13(3):197-216
24577401
Sci Signal. 2009 Jun 16;2(75):re4
19531804
Int J Mol Sci. 2015 Mar 24;16(4):6645-67
25811927
J Cell Physiol. 2010 Apr;223(1):36-48
20020487
Eur J Biochem. 2000 Oct;267(20):6158-65
11012668
Nat Chem Biol. 2015 Feb;11(2):141-7
25558972
J Med Chem. 2016 May 26;59(10 ):5102-8
27070779
J Med Chem. 2014 Jul 24;57(14):5871-92
24502334
Biochemistry. 1996 Jun 25;35(25):8465-72
8679605
Proc Natl Acad Sci U S A. 2004 Aug 31;101(35):12876-81
15326291
J Steroid Biochem Mol Biol. 2015 May;149:153-65
25727742
Gene. 1996 Nov 28;181(1-2):199-206
8973331
Can J Physiol Pharmacol. 2015 May;93(5):311-8
25741777
Arch Biochem Biophys. 1996 May 15;329(2):228-34
8638956
Science. 2002 May 17;296(5571):1313-6
12016314
Chem Biol. 2005 Aug;12(8):931-9
16125105
J Steroid Biochem Mol Biol. 2008 Dec;112(4-5):213-9
19000766
PLoS One. 2009 Jun 19;4(6):e5988
19543524
J Lipid Res. 2014 Jan;55(1):13-31
23564710
J Steroid Biochem Mol Biol. 2016 May;159:131-41
26970587
Endocrinology. 2006 Dec;147(12):5542-8
16946007
Biol Pharm Bull. 2000 Feb;23(2):133-9
10706373
J Med Chem. 2015 Oct 8;58(19):7881-7
26367019
Int J Biochem Cell Biol. 2008;40(11):2619-26
18573681
Exp Dermatol. 2016 Mar;25(3):231-2
26440881
J Lipid Res. 2013 Aug;54(8):2206-13
23723390
Mol Cancer Ther. 2006 Apr;5(4):797-808
16648549
Mol Cell Endocrinol. 2014 Mar 5;383(1-2):181-92
24382416
J Clin Endocrinol Metab. 2013 Feb;98(2):E298-303
23295467
Mol Endocrinol. 2010 Jun;24(6):1151-64
20371703
Mol Cell Endocrinol. 2011 Dec 5;347(1-2):11-6
21664245
Int J Biochem Cell Biol. 2014 Oct;55:24-34
25130438
Crit Rev Eukaryot Gene Expr. 2007;17(1):31-47
17341182
PLoS One. 2016 Feb 12;11(2):e0147979
26870941
Am J Physiol Cell Physiol. 2011 Mar;300(3):C526-41
21160030
J Steroid Biochem Mol Biol. 2012 Apr;129(3-5):163-71
22210453
FEBS Lett. 1999 Apr 9;448(2-3):278-82
10218492
Biochim Biophys Acta. 2011 Jan;1814(1):186-99
20619365
Exp Dermatol. 2011 Jan;20(1):7-13
21197695
Can J Physiol Pharmacol. 2015 May;93(5):349-54
25559384
Trends Endocrinol Metab. 2010 Jun;21(6):375-84
20149679
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14754-9
14657394
Dermatoendocrinol. 2013 Jan 1;5(1):7-19
24494038
Anticancer Res. 2012 Sep;32(9):3733-42
22993313
Anticancer Res. 2015 Feb;35(2):1143-51
25667505
Anticancer Res. 2012 Mar;32(3):739-46
22399586
Drug Metab Dispos. 2010 Sep;38(9):1553-9
20554701
Br J Cancer. 2011 Dec 6;105(12):1874-84
22095230
Nucl Recept Signal. 2009;7:e003
19381306
J Cell Biochem. 1999 Apr 1;73(1):106-13
10088729
Anticancer Res. 2016 Mar;36(3):1345-56
26977036
Anticancer Agents Med Chem. 2006 Jan;6(1):53-71
16475927
Int J Oncol. 2015 Sep;47(3):1084-96
26260259
FEBS J. 2014 Jul;281(14 ):3280-96
24893882
FASEB J. 2014 Jul;28(7):2775-89
24668754
Mol Endocrinol. 2012 Apr;26(4):574-82
22322599
J Steroid Biochem Mol Biol. 2015 Apr;148:72-8
25448743
PLoS One. 2010 Mar 26;5(3):e9907
20360850
Int J Mol Sci. 2013 Jan 18;14(1):1964-77
23334476
Drug Metab Dispos. 2011 Sep;39(9):1577-88
21677063
J Steroid Biochem Mol Biol. 2015 Jul;151:25-37
25448732